Pituitary adenoma & nuclear medicine: ...
Type de document :
Compte-rendu et recension critique d'ouvrage
PMID :
Titre :
Pituitary adenoma & nuclear medicine: Recent outcomes and ongoing developments
Auteur(s) :
Chevalier, Benjamin [Auteur]
Service Endocrinologie, diabétologie, maladies métaboliques et nutrition [LILLE - Endocrino]
Université Lille Nord (France)
Jannin, Arnaud [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Service Endocrinologie, diabétologie, maladies métaboliques et nutrition [LILLE - Endocrino]
Université Lille Nord (France)
Stephanie, Espiard [Auteur]
Service Endocrinologie, diabétologie, maladies métaboliques et nutrition [LILLE - Endocrino]
Université Lille Nord (France)
Recherche translationnelle sur le diabète - U 1190 [RTD]
Merlen, Emilie [Auteur]
Service Endocrinologie, diabétologie, maladies métaboliques et nutrition [LILLE - Endocrino]
Beron, Amandine [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Lion, Georges [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Vantyghem, Marie-Christine [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Université Lille Nord (France)
Service Endocrinologie, diabétologie, maladies métaboliques et nutrition [LILLE - Endocrino]
Huglo, Damien [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Université Lille Nord (France)
Cortet-Rudelli, Christine [Auteur]
Service Endocrinologie, diabétologie, maladies métaboliques et nutrition [LILLE - Endocrino]
Baillet, Clio [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Service Endocrinologie, diabétologie, maladies métaboliques et nutrition [LILLE - Endocrino]
Université Lille Nord (France)
Jannin, Arnaud [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Service Endocrinologie, diabétologie, maladies métaboliques et nutrition [LILLE - Endocrino]
Université Lille Nord (France)
Stephanie, Espiard [Auteur]
![refId](/themes/Mirage2//images/idref.png)
Service Endocrinologie, diabétologie, maladies métaboliques et nutrition [LILLE - Endocrino]
Université Lille Nord (France)
Recherche translationnelle sur le diabète - U 1190 [RTD]
Merlen, Emilie [Auteur]
Service Endocrinologie, diabétologie, maladies métaboliques et nutrition [LILLE - Endocrino]
Beron, Amandine [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Lion, Georges [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Vantyghem, Marie-Christine [Auteur]
![refId](/themes/Mirage2//images/idref.png)
Recherche translationnelle sur le diabète - U 1190 [RTD]
Université Lille Nord (France)
Service Endocrinologie, diabétologie, maladies métaboliques et nutrition [LILLE - Endocrino]
Huglo, Damien [Auteur]
![refId](/themes/Mirage2//images/idref.png)
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Université Lille Nord (France)
Cortet-Rudelli, Christine [Auteur]
Service Endocrinologie, diabétologie, maladies métaboliques et nutrition [LILLE - Endocrino]
Baillet, Clio [Auteur]
![refId](/themes/Mirage2//images/idref.png)
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Titre de la revue :
La Presse Médicale
Pagination :
104144
Éditeur :
Elsevier Masson
Date de publication :
2022-06-01
ISSN :
0755-4982
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
In order to explore pituitary adenoma (PA), magnetic resonance imaging (MRI) remains the cornerstone. However, there are some limitations and MRI can be non-conclusive. The development of additional imaging modalities like ...
Lire la suite >In order to explore pituitary adenoma (PA), magnetic resonance imaging (MRI) remains the cornerstone. However, there are some limitations and MRI can be non-conclusive. The development of additional imaging modalities like nuclear medicine explorations may help to confirm PA diagnosis, guide management and follow up. Nuclear medicine uses radiopharmaceuticals for imaging with single photon emission computed tomography (SPECT), or positron emission tomography (PET), coupled to CT scan. Radiopharmaceuticals products target specific cellular elements which allow to explore several biological pathways. Nuclear medicine may also be used for therapeutic purposes and recent developments of approach based on Peptide Receptor Radionuclide Therapy (PRRT) for treatment of aggressive PA and pituitary carcinoma will be reviewed. Several radiotracers have been studied in the context of PA, and the aim of this paper is to discuss their respective performances and clinical interest.Lire moins >
Lire la suite >In order to explore pituitary adenoma (PA), magnetic resonance imaging (MRI) remains the cornerstone. However, there are some limitations and MRI can be non-conclusive. The development of additional imaging modalities like nuclear medicine explorations may help to confirm PA diagnosis, guide management and follow up. Nuclear medicine uses radiopharmaceuticals for imaging with single photon emission computed tomography (SPECT), or positron emission tomography (PET), coupled to CT scan. Radiopharmaceuticals products target specific cellular elements which allow to explore several biological pathways. Nuclear medicine may also be used for therapeutic purposes and recent developments of approach based on Peptide Receptor Radionuclide Therapy (PRRT) for treatment of aggressive PA and pituitary carcinoma will be reviewed. Several radiotracers have been studied in the context of PA, and the aim of this paper is to discuss their respective performances and clinical interest.Lire moins >
Langue :
Anglais
Vulgarisation :
Non
Source :